Janssen Announces Phase 3b PIONEER AF-PCI Study Data Accepted for Late-Breaking Presentation at AHA Conference
Tweet Send to a Friend
Janssen Pharmaceuticals, Inc. (Janssen) announced that results from the Phase 3b PIONEER AF-PCI study with XARELTO (rivaroxaban) and new INVOKANA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE